NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

Nice, but as you know or should know, this is irrelevant to do with dcvax-l at this time.

Dabrafenib (both as monotherapy and in combination with trametinib) has proven to be efficacious in the 7% of LGG patients who have the BRAF V600E mutation.

As you know, NWBO will run a pediatric clinical trial before it is possibly approved for children but dcvax-l is currently only targeted for glioblastoma ie grade 4 glioma, not the low grade gliomas, and not the small number of LGG with BRAF V600E that dabrafenib therapy targets.